Annexon Biosciences Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures…
ANX005 Has Been Generally Well-Tolerated and Has Shown Full Target Engagement of C1q in the CSF Improvements in Clinical Outcome Measures Observed in Greater than 50% of All Evaluable Patients and 75% of Evaluable Patients with Excess…